^
Association details:
| Biomarker: | RBM10 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | PRT543 (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2159 - PRMT5 inhibitor PRT543 displays potent antitumor activity in U2AF1S34F and RBM10LOF spliceosome-mutant non-small cell lung cancer in vitro and in vivo
Published date:
03/09/2022
Excerpt:
Cell proliferation (10-day assay) was assessed in a panel of NSCLC cell lines treated with PRT543, either wild-type or harboring U2AF1S34F or RBM10LOF mutations. Strikingly, both U2AF1S34F and RBM10LOF cell lines were significantly more sensitive to PRT543 compared to wild-type cell lines. PRT543 induced significant dose-related tumor growth inhibition at well-tolerated doses in cell-line derived xenograft (CDX) models harboring the U2AF1S34F or RBM10LOF mutation.
